Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies
Open Access
- 1 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (Supplement) , S194-S201
Abstract
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. Durlobactam is a member of the diazabicyclooctane class of β-lactamase inhibitors with broad-spectrum serine β-lactamase activity. Sulbactam is a first-generation, narrow-spectrum β-lactamase inhibitor that also has intrinsic antibacterial activity against Acinetobacter spp. due to its ability to inhibit penicillin-binding proteins 1 and 3. The clinical utility of sulbactam for the treatment of contemporary Acinetobacter infections has been eroded over the last decades due to its susceptibility to cleavage by numerous β-lactamases present in this species. However, when combined with durlobactam, the activity of sulbactam is restored against this problematic pathogen. The following summary describes what is known about the molecular drivers of activity and resistance as well as results from surveillance and in vivo efficacy studies for this novel combination.Keywords
This publication has 40 references indexed in Scilit:
- TEM-1 -lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2013
- Early Insights into the Interactions of Different β-Lactam Antibiotics and β-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3Antimicrobial Agents and Chemotherapy, 2012
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Multidrug‐ResistantAcinetobacter baumannii:An Emerging Pathogen among Older Adults in Community Hospitals and Nursing HomesClinical Infectious Diseases, 2010
- Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health SystemAntimicrobial Agents and Chemotherapy, 2010
- Increasing Occurrence of Multidrug-Resistance in Acinetobacter baumannii Isolates From Four German University Hospitals, 2002–2006Infection, 2010
- Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptibleacinetobacter baumanniiFEMS Microbiology Letters, 1995
- Sulbactam: Biochemical Factors Involved in Its Synergy with AmpicillinClinical Infectious Diseases, 1986
- In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studiesDiagnostic Microbiology and Infectious Disease, 1985
- CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological CharacterizationAntimicrobial Agents and Chemotherapy, 1978